Rosuvastatin is linked to slightly increased risk of kidney failure compared with atorvastatin, underlining the need to start and stay low with patients who have chronic kidney disease, according to US researchers. 

Their study, of nearly a million patients initiating statin therapy, provides solid real-world data on proteinuria, haematuria and kidney failure with rosuvastatin, finding the risk increases in a dose–response manner.